Epidemiology, clinical characteristics, and virologic features of COVID-19 patients in Kazakhstan: A nation-wide retrospective cohort study.
COVID-19
Central Asia
Clinical characteristics
Disease risk factors
Disease severity
Kazakhstan
Molecular epidemiology
SARS-CoV-2
SARS-CoV-2 genomics
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
entrez:
21
4
2021
pubmed:
22
4
2021
medline:
22
4
2021
Statut:
ppublish
Résumé
The earliest coronavirus disease-2019 (COVID-19) cases in Central Asia were announced in March 2020 by Kazakhstan. Despite the implementation of aggressive measures to curb infection spread, gaps remain in the understanding of the clinical and epidemiologic features of the regional pandemic. We did a retrospective, observational cohort study of patients with laboratory-confirmed COVID-19 hospitalized in Kazakhstan between February and April 2020. We compared demographic, clinical, laboratory and radiological data of patients with different COVID-19 severities on admission. Logistic regression was used to assess factors associated with disease severity and in-hospital death. Whole-genome SARS-CoV-2 analysis was performed in 53 patients. Of the 1072 patients with laboratory-confirmed COVID-19 in March-April 2020, the median age was 36 years (IQR 24-50) and 484 (45%) were male. On admission, 683 (64%) participants had asymptomatic/mild, 341 (32%) moderate, and 47 (4%) severe-to-critical COVID-19 manifestation; 20 in-hospital deaths (1•87%) were reported by 5 May 2020. Multivariable regression indicated increasing odds of severe disease associated with older age (odds ratio 1•05, 95% CI 1•03-1•07, per year increase; p<0•001), the presence of comorbidities (2•34, 95% CI 1•18-4•85; p=0•017) and elevated white blood cell count (WBC, 1•13, 95% CI 1•00-1•27; p=0•044) on admission, while older age (1•09, 95% CI 1•06-1•13, per year increase; p<0•001) and male sex (5•63, 95% CI 2•06-17•57; p=0•001) were associated with increased odds of in-hospital death. The SARS-CoV-2 isolates grouped into seven phylogenetic lineages, O/B.4.1, S/A.2, S/B.1.1, G/B.1, GH/B.1.255, GH/B.1.3 and GR/B.1.1.10; 87% of the isolates were O and S sub-types descending from early Asian lineages, while the G, GH and GR isolates were related to lineages from Europe and the Americas. Older age, comorbidities, increased WBC count, and male sex were risk factors for COVID-19 disease severity and mortality in Kazakhstan. The broad SARS-CoV-2 diversity suggests multiple importations and community-level amplification predating travel restriction. Ministry of Education and Science of the Republic of Kazakhstan.
Sections du résumé
BACKGROUND
BACKGROUND
The earliest coronavirus disease-2019 (COVID-19) cases in Central Asia were announced in March 2020 by Kazakhstan. Despite the implementation of aggressive measures to curb infection spread, gaps remain in the understanding of the clinical and epidemiologic features of the regional pandemic.
METHODS
METHODS
We did a retrospective, observational cohort study of patients with laboratory-confirmed COVID-19 hospitalized in Kazakhstan between February and April 2020. We compared demographic, clinical, laboratory and radiological data of patients with different COVID-19 severities on admission. Logistic regression was used to assess factors associated with disease severity and in-hospital death. Whole-genome SARS-CoV-2 analysis was performed in 53 patients.
FINDINGS
RESULTS
Of the 1072 patients with laboratory-confirmed COVID-19 in March-April 2020, the median age was 36 years (IQR 24-50) and 484 (45%) were male. On admission, 683 (64%) participants had asymptomatic/mild, 341 (32%) moderate, and 47 (4%) severe-to-critical COVID-19 manifestation; 20 in-hospital deaths (1•87%) were reported by 5 May 2020. Multivariable regression indicated increasing odds of severe disease associated with older age (odds ratio 1•05, 95% CI 1•03-1•07, per year increase; p<0•001), the presence of comorbidities (2•34, 95% CI 1•18-4•85; p=0•017) and elevated white blood cell count (WBC, 1•13, 95% CI 1•00-1•27; p=0•044) on admission, while older age (1•09, 95% CI 1•06-1•13, per year increase; p<0•001) and male sex (5•63, 95% CI 2•06-17•57; p=0•001) were associated with increased odds of in-hospital death. The SARS-CoV-2 isolates grouped into seven phylogenetic lineages, O/B.4.1, S/A.2, S/B.1.1, G/B.1, GH/B.1.255, GH/B.1.3 and GR/B.1.1.10; 87% of the isolates were O and S sub-types descending from early Asian lineages, while the G, GH and GR isolates were related to lineages from Europe and the Americas.
INTERPRETATION
CONCLUSIONS
Older age, comorbidities, increased WBC count, and male sex were risk factors for COVID-19 disease severity and mortality in Kazakhstan. The broad SARS-CoV-2 diversity suggests multiple importations and community-level amplification predating travel restriction.
FUNDING
BACKGROUND
Ministry of Education and Science of the Republic of Kazakhstan.
Identifiants
pubmed: 33880458
doi: 10.1016/j.lanepe.2021.100096
pii: S2666-7762(21)00073-9
pmc: PMC8050615
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100096Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Lancet Microbe. 2020 Nov;1(7):e281
pubmed: 33521728
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Anaesthesia. 2021 Mar;76 Suppl 3:11-12
pubmed: 33015828
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
J Korean Med Sci. 2020 Jun 22;35(24):e227
pubmed: 32567261
Paediatr Int Child Health. 2021 Feb;41(1):76-82
pubmed: 33315538
Clin Infect Dis. 2021 Jul 1;73(1):1-11
pubmed: 33035307
Radiol Med. 2020 Jul;125(7):636-646
pubmed: 32500509
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
Nat Commun. 2020 Oct 9;11(1):5110
pubmed: 33037213
Nat Med. 2020 Apr;26(4):506-510
pubmed: 32284616
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
JAMA. 2020 Apr 28;323(16):1549-1550
pubmed: 32176764
Nat Commun. 2020 Sep 1;11(1):4376
pubmed: 32873808
EClinicalMedicine. 2020 Dec;29:100630
pubmed: 33200120
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
EClinicalMedicine. 2020 Aug;25:100471
pubmed: 32840491
Lancet. 2020 Apr 25;395(10233):1382-1393
pubmed: 32277878
Lancet Infect Dis. 2020 Sep;20(9):1043-1050
pubmed: 32539988
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968